BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ

Active Ingredient: Nogapendekin alfa

Indication for Nogapendekin alfa

Population group: only adults (18 years old or older)
Therapeutic intent: Adjunct intent

Nogapendekin alfa inbakicept-pmln in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

For this indication, competent medicine agencies globally authorize below treatments:

400 ug with BCG once a week for 6 weeks and thereafter 400 ug with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses)

For:

Dosage regimens

Intravesical, 400 micrograms nogapendekin alfa, once weekly, 6 doses in total, over the duration of 3 months. Afterwards, intravesical, 400 micrograms nogapendekin alfa, once weekly, 3 doses in total, over the duration of 3 months. Afterwards, intravesical, 400 micrograms nogapendekin alfa, once weekly, 3 doses in total, over the duration of 3 months. Afterwards, intravesical, 400 micrograms nogapendekin alfa, once weekly, 3 doses in total, over the duration of 3 months. Afterwards, intravesical, 400 micrograms nogapendekin alfa, once weekly, 3 doses in total, over the duration of 6 months. Afterwards, intravesical, 400 micrograms nogapendekin alfa, once weekly, 3 doses in total, over the duration of 6 months. Afterwards, in case that there is very good treatment response, intravesical, 400 micrograms nogapendekin alfa, once weekly, 3 doses in total, over the duration of 6 months. This step is repeated 3 times.

Detailed description

For induction: nogapendekin alfa inbakicept is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if complete response is not achieved at month 3.

For maintenance: After BCG and nogapendekin alfa inbakicept induction therapy, nogapendekin alfa inbakicept is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses). For patients with an ongoing complete response at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations.

The recommended duration of treatment is until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months.

Dosage considerations

For intravesical use only. Do NOT administer by subcutaneous or intravenous or intramuscular routes.

Active ingredient

Nogapendekin alfa

Nogapendekin alfa inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans-presented by the IL-15 receptor α to the shared IL-2/IL-15 receptor (βc and γc) on the surface of CD4+ and CD8+ T cells and NK cells. Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8+, and memory T cells without proliferation of immuno-suppressive Treg cells.

Read more about Nogapendekin alfa

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.